Arrowhead Pharmaceuticals, Inc.
ARWR
주식 순위
#2378
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena,... Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
주가
$58.86
시가총액
$8.31B
변동 (1일)
2.85%
변동 (1년)
53.00%
국가
US
거래 Arrowhead Pharmaceuticals, Inc. (ARWR)
카테고리
Healthcare
Arrowhead Pharmaceuticals, Inc. (ARWR)의 발행 주식 수
June 2026 기준 발행 주식 수: 143.38M
Arrowhead Pharmaceuticals, Inc.의 최신 재무 보고서와 주가에 따르면 현재 발행 주식 수는 143.38M입니다. September 2024 말 기준 회사는 119.78M주를 발행했습니다. 발행 주식 수는 일반적으로 주식 분할이나 자사주 매입에 의해 영향을 받습니다.
Arrowhead Pharmaceuticals, Inc. (ARWR)의 발행 주식 수 기록 (2000 ~ 2026)
매년 말 기준 발행 주식 수
| 연도 | 발행 주식 수 | 변화 |
|---|---|---|
| 2026 (TTM) | 143.38M | 7.19% |
| 2025 | 133.76M | 11.67% |
| 2024 | 119.78M | 11.62% |
| 2023 | 107.31M | 1.79% |
| 2022 | 105.43M | 1.62% |
| 2021 | 103.75M | 3.00% |
| 2020 | 100.72M | 7.31% |
| 2019 | 93.86M | 12.22% |
| 2018 | 83.64M | 14.34% |
| 2017 | 73.15M | 19.94% |
| 2016 | 60.99M | 6.33% |
| 2015 | 57.36M | 22.29% |
| 2014 | 46.90M | 95.79% |
| 2013 | 23.96M | 115.45% |
| 2012 | 11.12M | 54.83% |
| 2011 | 7.18M | 11.61% |
| 2010 | 6.43M | 42.45% |
| 2009 | 4.52M | 15.25% |
| 2008 | 3.92M | 9.27% |
| 2007 | 3.59M | 12.25% |
| 2006 | 3.20M | 25.86% |
| 2005 | 2.54M | 90.80% |
| 2004 | 1.33M | 16,357.72% |
| 2003 | 8.09K | 6.62% |
| 2002 | 7.58K | 6.00% |
| 2001 | 7.15K | 1.32% |
| 2000 | 7.06K | 0.00% |
유사 기업 또는 경쟁사의 발행 주식 수
| 회사 | 발행 주식 수 | 차이 | 국가 |
|---|---|---|---|
| 253.90M | 77.08% |
US
|
|
| 396.00M | 176.19% |
US
|
|
| 478.91M | 234.02% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -56.63% |
NL
|
